Antianemic Treatment of Cancer Patients in German Routine Practice: Data from a Prospective Cohort Study—The Tumor Anemia Registry

Table 1

Characteristics of patients receiving antianemic treatments in German routine practice.

	Operable solid tumor ()					Inoperable solid tumor ()					Hematological malignancy ()					Total
Day 1 treatment	Transfusion	ESA	IV iron	ESA + IV iron		Transfusion	ESA	IV iron	ESA + IV iron		Transfusion	ESA	IV iron	ESA + IV iron
Number of patients []	114	51	30	12		362	108	102	34		95	37	10	7		962
Sex
Male [%]	36.8	27.5	40.0	50.0		50.0	43.5	52.9	58.8		57.9	51.4	80.0	57.1		48.0
Age at start of therapy
Mean ± StD	66.0 ± 12.8	64.2 ± 12.5	66.2 ± 9.5	66.4 ± 8.8		66.6 ± 10.6	64.4 ± 9.7	66.8 ± 10.6	69.1 ± 9.2		69.2 ± 11.5	64.8 ± 17.0	67.7 ± 14.3	67.4 ± 10.4		66.5 ± 11.3
CCI [0–36]
Mean ± StD	0.6 ± 1.6	0.5 ± 0.9	0.5 ± 0.9	0.8 ± 1.1		0.8 ± 1.3	0.6 ± 1.2	0.6 ± 1.1	0.6 ± 1.0		0.5 ± 0.9	0.8 ± 1.3	0.3 ± 0.7	1.4 ± 2.9		0.7 ± 1.2
Karnofsky Index [0–100]
Mean ± StD	81.6 ± 11.5	82.2 ± 9.2	87.7 ± 8.2	86.7 ± 4.9		78.7 ± 12.8	82.5 ± 8.8	78.8 ± 12.0	80.6 ± 10.7		82.6 ± 12.5	82.2 ± 10.0	77.0 ± 14.9	88.6 ± 6.9		80.7 ± 118
Most frequent solid cancers [%]
Breast	16.7	41.2	16.7	8.3		14.1	25.0	11.8	14.7		—	—	—	—		14.7
Colorectal	15.8	13.7	30.0	33.3		9.1	5.6	20.6	2.9		—	—	—	—		10.3
Lung (NSCLC)	10.5	11.8	3.3	16.7		10.8	15.7	3.9	5.9		—	—	—	—		8.6
Tumor therapy [%]
No therapy	6.1	—	3.3	—		2.5	0.9	2.0	—		6.3	5.4	20.0	—		3.1
Chemotherapy	92.1	98.0	93.3	100.0		88.1	95.4	86.3	94.1		76.8	81.1	40.0	85.7		88.4
Other	1.8	2.0	3.4	—		90.6	96.3	88.3	5.9		16.9	13.5	40.0	14.3		91.5
Baseline Hb
Median [g/dL]	8.7	9.3	9.6	9.6		8.6	9.5	9.6	9.4		8.5	9.2	9.6	10.8		8.9

Charlson Comorbidity Index.